Current ongoing clinical trials:

TRIAL IN Treatment Resistant Major Depressive Disorder (RAPID)

The RAPID trial is a double-blind, randomized, sham-controlled study of LFMS in treatment resistant major depressive disorder patients. The National Institute of Mental Health is fully funding the trial under its RAPID program. Led by Massachusetts General Hospital, 6 major US research centers are participating in the study. The RAPID trial tests 20 minute LFMS treatment sessions over 2 and 4 consecutive days vs. sham and measures the effect durability for one month.

This study has closed and analysis is underway.

For more information, please click here

 

DOSE OPTIMIZATION STUDY (SOLIDD)

The dose optimization study is a double-blind, randomized, sham-controlled study of LFMS in treatment resistant major depressive disorder (120 patients). This trial is designed to identify the optimal treatment protocol (e.g., session length, number of sessions) and treatment effect durability over one month. 

For more information, please click here

 

WEILL CORNELL BIOMARKER STUDY

The Weill Cornell Imaging study is a double-blind, randomized, sham-controlled study of LFMS effects on brain circuitry of adults with treatment-resistant major depressive disorder. Using advanced MRI techniques, the study goal is to help better understand the physiological effects and mechanism of action of LFMS.

For more information, please click here